Lexeo Therapeutics has announced an $80 million equity financing round to support the development of genetic medicines targeting cardiovascular diseases. The financing was led by Frazier Life Sciences and Janus Henderson Investors. This funding round follows a previous $95 million raise approximately one year ago, which occurred before key data releases and accelerated approval guidance. The current raise was conducted at a valuation of $2.83 per share, including warrants, with some previous investors not participating this time. Additionally, Lexeo is developing a potentially safer AAVrh10 vector that requires a lower viral dose compared to Rocket Pharmaceuticals' AAV9 vector. Industry observers suggest Lexeo could leverage the new capital to initiate a program focused on Danon disease, especially as Rocket Pharmaceuticals appears to be stepping back from this area. Separately, GlycoEra secured $130 million in a Series B funding round to advance extracellular degraders for autoimmune diseases.